<SEC-DOCUMENT>0000950170-25-060456.txt : 20250429
<SEC-HEADER>0000950170-25-060456.hdr.sgml : 20250429
<ACCEPTANCE-DATETIME>20250429184810
ACCESSION NUMBER:		0000950170-25-060456
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250429
DATE AS OF CHANGE:		20250429

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91173
		FILM NUMBER:		25890108

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001121404</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, Euro 0.05 nominal value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>04/23/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001598599</issuerCik>
        <issuerName>Innate Pharma SA</issuerName>
        <issuerCusip>45781K105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">117, Avenue de Luminy</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Marseille</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">I0</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">13009</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>SANOFI</reportingPersonName>
      <citizenshipOrOrganization>I0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>8345387</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>8345387</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8345387</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.05</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>The percentage is based on 92,157,148 ordinary shares outstanding (excluding treasury shares held by the Issuer) as of April 25, 2025, as reported by the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Innate Pharma SA</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>117, Avenue de Luminy, 13009 Marseille, France</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Sanofi</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>46, avenue de la Grande Armee, 75017 Paris, France</principalBusinessOfficeOrResidenceAddress>
        <citizenship>The Republic of France </citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>8,345,387 shares</amountBeneficiallyOwned>
        <classPercent>9.05</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>8,345,387 shares</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0 shares</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>8,345,387 shares</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0 shares</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Sanofi-Aventis Participations SAS         8,345,387 shares            9.05%
The shares are held of record by Sanofi-Aventis Participations SAS, the reporting person's indirect, wholly owned subsidiary.
</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>The response of the Reporting Person to Item 6 is incorporated herein by reference.  </subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>SANOFI</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Alexandra Roger</signature>
        <title>Alexandra Roger, Head of Legal Corporate and Finance</title>
        <date>04/29/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>*Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.</signatureComments>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
